
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is supported by a resilient growth outlook as it maintains expectations for 2026 high-single digit top-line growth even after a downward revision to Baqsimi, indicating underlying demand strength across the portfolio. Baqsimi remains a meaningful contributor with peak sales expectations of $250MM-$275MM, and margins are expected to improve in 2H26 as the company discontinues a small amount of international sales, which should enhance profitability. The recent launch of ipratropium bromide HFA has not faced additional competition and could become a $30MM-$40MM sales opportunity, reinforcing the company’s ability to convert product launches into durable revenue growth.
Bears say
Amphastar Pharma is facing a fragile growth profile as core products are being pressured by competition and pricing erosion, with injectable glucagon falling 42% in 2Q26 to $11.9M after Viatris entered generic glucagon and generic epinephrine also softened. Baqsimi, despite 17% prescription growth in 1Q26 and 2Q26, saw sales decline to $32.4M and $45.5M because higher rebates, 340B discounts, and an unfavorable channel mix drove lower net selling prices and margin erosion. The company also lacks near-term catalysts, as next ANDA approvals and potential new products are not expected until 2027, while higher R&D spending and reduced 2027E EBITDA of $204M support a cautious outlook.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares